Up another 16% TODAY, see why this AI-picked medtech stock is now up +92%
Haemonetics Corporation (NYSE:HAE) rose 15.9% after announcing a supply agreement with CSL Plasma, adding to its 91.88% surge since being identified by InvestingPro's AI models. The company reported Q1 2027 revenue of $339.4M and adjusted EPS of $1.14, raising its full-year revenue growth outlook to 5-8%. InvestingPro's AI-powered stock picker has identified multiple stocks with significant gains, including Haemonetics, which was highlighted for its valuation, profitability, and growth potential
How this was made
The 30-second read
Why it matters
The contract provides a tangible commercial milestone and supports the narrative of recurring, integrated hardware and software revenue streams.
Market read
Traders can treat the CSL Plasma supply agreement as a fresh, deal-driven catalyst for HAE, with potential for momentum trading and guidance sensitivity.
What to watch
Execution risk (device deployment timelines, adoption rates), competitive tendering in plasma networks, and whether guidance raises are conservative versus aggressive.
Background
The piece frames Haemonetics as a compounding medtech winner, then attributes today’s move to a newly disclosed supply agreement with CSL Plasma.
Ticker impact
Haemonetics surged 15.9% after announcing a new long-term U.S. supply agreement with CSL Plasma to deploy NexSys PCS devices with Persona PLUS technology.
Bullish bias for continued follow-through, with elevated volatility around deal execution and any incremental guidance updates.
The article ties today’s jump to a specific contract, describes the deployed product scope, and adds management guidance and recent financial performance figures.
Market effects
Reinforces demand and contracting strength in plasma collection and blood management medtech, potentially lifting sentiment for adjacent medtech platforms.
Primarily U.S.-listed medtech sentiment; broader index weakness is attributed to yields and oil, not medtech fundamentals.
Deal is U.S.-focused but signals global pharma and plasma network spending appetite, which can affect cross-border medtech expectations.
Counterpoint
A single supply agreement may already be partially priced after a large run; upside may depend on ramp speed, utilization, and reimbursement dynamics.
Key entities
- companyHaemonetics Corporation
Medtech provider of automated plasma collection systems, blood management software, and vascular closure devices.
- companyCSL Plasma
Plasma collection network that will deploy Haemonetics NexSys PCS devices with Persona PLUS technology under the supply agreement.
